Antithrombotic Treatment for Chronic Coronary Syndrome: Evidence and Future Perspectives
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Background: The clinical presentation of coronary artery disease can range from asymptomatic, through stable disease in the form of chronic coronary syndrome, to acute coronary syndrome. Chronic coronary syndrome is a frequent condition, and secondary prevention of ischaemic events is essential. Summary: Antithrombotic therapy is a key component of secondary prevention strategies, and it may vary in type and intensity depending on patient characteristics, comorbidities, and revascularisation modalities. Dual antiplatelet therapy is the default strategy in patients with chronic coronary syndrome and recent coronary stent implantation, while antiplatelet monotherapy is commonly prescribed for long-term prevention of cardiovascular events. Oral anticoagulation, in combination with antiplatelet therapy or alone, is used in patients with, e.g., concomitant atrial fibrillation or venous thromboembolism. Key Messages: This review provides an overview of antithrombotic treatment strategies in patients with chronic coronary syndrome. Key messages from current guidelines are conveyed, and we provide future perspectives on long-term antithrombotic strategies.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Cardiology (Switzerland) |
Sider (fra-til) | 1-11 |
Antal sider | 11 |
ISSN | 0008-6312 |
DOI | |
Status | E-pub ahead of print - 2024 |
Bibliografisk note
Publisher Copyright:
© 2024 S. Karger AG, Basel.
ID: 394709190